Osteoporosis Treatment Market Overview

Global Osteoporosis Treatment Market was valued at USD 12.61 billion in 2021 and is expected to reach USD 17.39 billion by the year 2028, at a CAGR of 4.7%.

Bones play an important role in movement and supporting the framework of the human body. Bones are made up of calcium, magnesium, and phosphorous. Bones play a very essential role in supporting the vital organs of the body. Osteoporosis is a medical condition that causes bones to become weak and brittle. Osteoporosis makes bone so brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture. Osteoporosis mainly affects the bones in the hip, wrist, and spine region. As bones are living tissue and are constantly broken down and replaced, osteoporosis occurs when the formation of new bone doesn’t keep up with the loss of old bone. Men and women of all races are equally affected by osteoporosis. However, white and Asian women, particularly older women who have passed menopause, are more at risk. Medications such as cancer medications, and glucocorticoid steroids have the potential to increase the risk of developing osteoporosis. Osteoporosis is also called a silent disease as there are no symptoms until a bone is broken or there is a fracture in one or more vertebrae. The growing prevalence of osteoporosis in older individuals is stimulating the expansion of the osteoporosis treatment market over the forecast period.

COVID-19 Impact on Osteoporosis Treatment Market:

The outbreak of COVID-19 has severely impacted the functioning of several industry verticals. COVID-19 had a tremendous negative impact on the world economy, according to many economic indices. Numerous international trade and economic activities experienced adverse effects of the pandemic. For instance, several countries imposed a ban on exports and import activities. In addition, an international movement of passengers was also suspended. It became difficult for the pharmaceutical companies to recruit candidates for clinical trials of several pipeline drugs. These included the clinical trials of drugs focusing on osteoporosis. The COVID-19 protocol such as lockdown prevented participants to visit the clinical sites. Furthermore, COVID-19 hampered the clinical studies as participants were unwilling to visit the clinical sites due to the fear of being getting infected with the virus. COVID-19 pandemic boosted telemedicine consultations delayed DXA scanning (an imaging test that measures the bone density), interrupted supply of medications, and decreased the parenteral medication delivery. To summarize, the COVID-19 pandemic negatively affected the clinical trials of various pipeline drugs that were manufactured for the treatment of osteoporosis.

Key Factors and Market Dynamics of Osteoporosis Treatment:

Drivers:

The growing awareness about osteoporosis and the early detection of disease has increased the adoption rate of osteoporosis treatment across the globe. Several women after menopause have reported hip, vertebral, and other severe fractures thus, the growing postmenopausal women population is propelling the expansion of the osteoporosis treatment market in the projected timeframe. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporosis fracture every 3 seconds. The foundation also stated that 1 in 3 women and 1 in 5 men over the age of 50 will experience osteoporosis fractures once in a lifetime. By 2050, the incidence of hip fracture is projected to reach 310% & 240% in men and women respectively.

The rise in the number of individuals suffering from calcium deficiency puts them in a medical condition having low bone mass (osteopenia). Osteopenia increases the chances of individual getting osteoporosis. In addition to this, treatment of certain medical disorders such as endocrine and hormonal diseases, gastrointestinal diseases, rheumatoid arthritis, certain types of cancer, HIV/AIDS, and anorexia nervosa can increase the risk of osteoporosis. Moreover, the IT working population has low levels of physical activity and prolonged periods of inactivity may increase the rate of bone loss. The rising prevalence of drinking and smoking population may contribute to increasing cases of osteoporosis in the upcoming future thus, strengthening the development of the osteoporosis treatment market throughout the forecast period.

Restraints:

Unawareness about the benefits of the osteoporosis treatment procedures and the negligence shown by individuals towards screening methods to diagnose osteoporosis are the main factors hindering the expansion of the market in the forecast period. Individuals taking bisphosphonates may experience an upset stomach or heartburn. People taking denosumab may experience lower calcium levels and may have skin infections at the site of injection. Similarly, other medications can cause dizziness, blood clot, loss of weight, osteonecrosis (bone loss in the jaw), and muscle pain thus, restraining the growth of the osteoporosis treatment market in the forecast period.

Opportunities:

The growing R&D activities for the development of novel drugs that can treat osteoporosis without having side effects on the body are creating a profitable opportunity for the manufacturer. Across the globe, there has been a significant rise in the number of individuals suffering from osteoporosis and other medical conditions that promote osteoporosis. It is estimated that more than 200 million individuals worldwide are suffering from osteoporosis. The majority of this population lives in developing regions. Thus, market players can target these regions to increase their revenue and provide top-class medications to these individuals at an affordable rate. Furthermore, the governments in this region also support the R&D activities of manufacturers thus, generating a lucrative opportunity for the market players. 

Market Segmentation

Segmentation of Osteoporosis Treatment Market:

Depending on drug class, the bisphosphonates segment is forecasted to have the highest share of the osteoporosis treatment market throughout the forecast period. Bisphosphonates have been shown to reduce the risk of fracture in people with established osteoporosis or those at high risk of fracture. In contrast, significant problems linked with bisphosphonate usages, such as Osteonecrosis of the jaw (ONJ) and atypical femur fractures, are quite rare. It also reduces the risk of hip and spine fractures by 35%. Moreover, bisphosphonates come in many different forms such as Actonel-a tablet form and Boniva-an intravenous injection. Bisphosphonates are also believed to prevent fractures in the long run even when the individual is no longer taking the medication thus, driving the growth of this segment.

Depending on the route of administration, the oral segment is predicted to lead the osteoporosis treatment market throughout the forecast period. This is the most preferred route for drug administration. Drugs that are administered orally are generally less expensive as compared to other forms. Moreover, these are easily self-administered by patients. Oral medications are simple and convenient as well these are non-invasive. The injectable segment is anticipated to register the highest CAGR in the projected period attributed to the immediate effect of these medications. Additionally, injectables have a rapid mode of action and exhibit improved bioavailability thus, strengthening the development of this segment.

Regional Analysis of Osteoporosis Treatment Market:

The Asia-Pacific region is anticipated to dominate the osteoporosis treatment market over the forecast period attributed to the rise in the number of geriatric populations. In India, around 50 million people are estimated to be either osteoporotic with less than T-score 2.5 or have a low bone mass with T-Score ranging between 1 to 2.5. This huge number of individuals is creating a lucrative opportunity for market players to target developing regions and launch new products that can aid in treating the symptoms of osteoporosis. Moreover, China, Japan, Korea, and Australia are the other prominent countries in this region that are consolidating the development of the osteoporosis treatment market in this region.

The North American region is expected to trail behind the Asia-Pacific region in terms of the expansion of the osteoporosis treatment market. In America near about 10 million people are suffering from osteoporosis and about 44 million have low bone density thus, placing them at increased risk of developing osteoporosis. One in every two women and one in every four men may break a bone as a result of osteoporosis over their lifetime. In women, the prevalence is higher than that of heart disease, stroke, and breast cancer combined. According to the National Osteoporosis Foundation, osteoporosis-related bone fractures cost individuals and the healthcare system $19 billion each year. Additionally, experts predict that by 2025, three million fractures will be due to osteoporosis and it will result in US$ 25.3 billion in costs. Thus, the growing prevalence of the disease in this region is driving the growth of the osteoporosis treatment market over the projected period.

The osteoporosis treatment market in the European region is anticipated to develop at a significant growth rate over the forecast period. According to the International Osteoporosis Foundation, the total cost of osteoporotic fractures in Europe was estimated at US$ 64.5 billion in 2019. Hip fractures were estimated to account for 57% of the total cost while vertebral fractures, forearm fractures, and others cost 10%, 2%, and 32% respectively. The presence of top-tier research institutions and the supportive government regulations for manufacturing novel drugs to treat osteoporosis are the main factors uplifting the growth of the market in this region

Players Covered in Osteoporosis Treatment Market are :

  • Amgen Inc. (US)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Radius Health Inc. (the US)
  • Merck & Co. Inc. (US)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (US)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Allergan Plc (Ireland)
  • Eli Lily and Company (US) and other major players.

Recent Industry Developments in Osteoporosis Treatment Market:

  • In October 2021, Radius Health, Inc. announced the findings of the ATOM study, which assessed abaloparatide 80 mcg subcutaneous (SC) for usage in males with osteoporosis. The study reported favorable topline findings, for instance, patients who received abaloparatide-SC had an average rise of 8.5 percent in LS BMD, whereas those who received the placebo had an average increase of 1.2 percent.
  • In July 2021, Sun Pharmaceuticals got a green signal from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for the manufacturing and marketing of its Teriparatide injection in a pre-filled pen 600mcg/2.4 ml (Synthetic origin). Teriparatide is a recombinant hormone that is mainly administered for the treatment of osteoporosis in men and postmenopausal women who are at high risk of having a fracture.

Global Osteoporosis Treatment Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 12.61 Bn.

Forecast Period 2022-28 CAGR:

4.7%

Market Size in 2028:

USD 17.39 Bn.

Segments Covered:

By Drug Class

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Rank Ligand Inhibitors
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • The Growing Awareness About Osteoporosis

Key Market Restraints:

  • Negligence Shown by Individuals Towards Screening Methods

Key Opportunities:

  • Growing R&D Activities for the Development of Novel Drugs

Companies Covered in the report:

  • Amgen Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Radius Health Inc. (the US), Merck & Co. Inc. (US), Novartis International AG (Switzerland), and Other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Drug Class
 3.2 By Route of Administration

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Osteoporosis Treatment Market by Drug Class
 5.1 Osteoporosis Treatment Market Overview Snapshot and Growth Engine
 5.2 Osteoporosis Treatment Market Overview
 5.3 Bisphosphonates
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Bisphosphonates: Grographic Segmentation
 5.4 Parathyroid Hormone Therapy
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Parathyroid Hormone Therapy: Grographic Segmentation
 5.5 Rank Ligand Inhibitors
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Rank Ligand Inhibitors: Grographic Segmentation
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Grographic Segmentation

Chapter 6: Osteoporosis Treatment Market by Route of Administration
 6.1 Osteoporosis Treatment Market Overview Snapshot and Growth Engine
 6.2 Osteoporosis Treatment Market Overview
 6.3 Oral
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Oral: Grographic Segmentation
 6.4 Injectable
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Injectable: Grographic Segmentation
 6.5 Others
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Others: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Osteoporosis Treatment Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Ansoff Matrix
  7.1.5 Osteoporosis Treatment Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Osteoporosis Treatment Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 AMGEN INC.
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 F. HOFFMANN-LA ROCHE AG
 7.4 RADIUS HEALTH INC.
 7.5 MERCK & CO. INC.
 7.6 NOVARTIS INTERNATIONAL AG
 7.7 PFIZER INC.
 7.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
 7.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
 7.10 TEVA PHARMACEUTICAL INDUSTRIES LTD
 7.11 ALLERGAN PLC
 7.12 ELI LILY & COMPANY
 7.13 OTHER MAJOR PLAYERS

Chapter 8: Global Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Drug Class
  8.2.1 Bisphosphonates
  8.2.2 Parathyroid Hormone Therapy
  8.2.3 Rank Ligand Inhibitors
  8.2.4 Others
 8.3 Historic and Forecasted Market Size By Route of Administration
  8.3.1 Oral
  8.3.2 Injectable
  8.3.3 Others

Chapter 9: North America Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Drug Class
  9.4.1 Bisphosphonates
  9.4.2 Parathyroid Hormone Therapy
  9.4.3 Rank Ligand Inhibitors
  9.4.4 Others
 9.5 Historic and Forecasted Market Size By Route of Administration
  9.5.1 Oral
  9.5.2 Injectable
  9.5.3 Others
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Drug Class
  10.4.1 Bisphosphonates
  10.4.2 Parathyroid Hormone Therapy
  10.4.3 Rank Ligand Inhibitors
  10.4.4 Others
 10.5 Historic and Forecasted Market Size By Route of Administration
  10.5.1 Oral
  10.5.2 Injectable
  10.5.3 Others
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Drug Class
  11.4.1 Bisphosphonates
  11.4.2 Parathyroid Hormone Therapy
  11.4.3 Rank Ligand Inhibitors
  11.4.4 Others
 11.5 Historic and Forecasted Market Size By Route of Administration
  11.5.1 Oral
  11.5.2 Injectable
  11.5.3 Others
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Drug Class
  12.4.1 Bisphosphonates
  12.4.2 Parathyroid Hormone Therapy
  12.4.3 Rank Ligand Inhibitors
  12.4.4 Others
 12.5 Historic and Forecasted Market Size By Route of Administration
  12.5.1 Oral
  12.5.2 Injectable
  12.5.3 Others
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Osteoporosis Treatment Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Drug Class
  13.4.1 Bisphosphonates
  13.4.2 Parathyroid Hormone Therapy
  13.4.3 Rank Ligand Inhibitors
  13.4.4 Others
 13.5 Historic and Forecasted Market Size By Route of Administration
  13.5.1 Oral
  13.5.2 Injectable
  13.5.3 Others
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

Global Osteoporosis Treatment Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 12.61 Bn.

Forecast Period 2022-28 CAGR:

4.7%

Market Size in 2028:

USD 17.39 Bn.

Segments Covered:

By Drug Class

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Rank Ligand Inhibitors
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • The Growing Awareness About Osteoporosis

Key Market Restraints:

  • Negligence Shown by Individuals Towards Screening Methods

Key Opportunities:

  • Growing R&D Activities for the Development of Novel Drugs

Companies Covered in the report:

  • Amgen Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Radius Health Inc. (the US), Merck & Co. Inc. (US), Novartis International AG (Switzerland), and Other major players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. OSTEOPOROSIS TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. OSTEOPOROSIS TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. OSTEOPOROSIS TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. OSTEOPOROSIS TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. OSTEOPOROSIS TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. OSTEOPOROSIS TREATMENT MARKET BY DRUG CLASS
TABLE 008. BISPHOSPHONATES MARKET OVERVIEW (2016-2028)
TABLE 009. PARATHYROID HORMONE THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. RANK LIGAND INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. OSTEOPOROSIS TREATMENT MARKET BY ROUTE OF ADMINISTRATION
TABLE 013. ORAL MARKET OVERVIEW (2016-2028)
TABLE 014. INJECTABLE MARKET OVERVIEW (2016-2028)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 016. NORTH AMERICA OSTEOPOROSIS TREATMENT MARKET, BY DRUG CLASS (2016-2028)
TABLE 017. NORTH AMERICA OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 018. N OSTEOPOROSIS TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 019. EUROPE OSTEOPOROSIS TREATMENT MARKET, BY DRUG CLASS (2016-2028)
TABLE 020. EUROPE OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 021. OSTEOPOROSIS TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 022. ASIA PACIFIC OSTEOPOROSIS TREATMENT MARKET, BY DRUG CLASS (2016-2028)
TABLE 023. ASIA PACIFIC OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 024. OSTEOPOROSIS TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA OSTEOPOROSIS TREATMENT MARKET, BY DRUG CLASS (2016-2028)
TABLE 026. MIDDLE EAST & AFRICA OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 027. OSTEOPOROSIS TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 028. SOUTH AMERICA OSTEOPOROSIS TREATMENT MARKET, BY DRUG CLASS (2016-2028)
TABLE 029. SOUTH AMERICA OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 030. OSTEOPOROSIS TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 031. AMGEN INC.: SNAPSHOT
TABLE 032. AMGEN INC.: BUSINESS PERFORMANCE
TABLE 033. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 034. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. F. HOFFMANN-LA ROCHE AG: SNAPSHOT
TABLE 035. F. HOFFMANN-LA ROCHE AG: BUSINESS PERFORMANCE
TABLE 036. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 037. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. RADIUS HEALTH INC.: SNAPSHOT
TABLE 038. RADIUS HEALTH INC.: BUSINESS PERFORMANCE
TABLE 039. RADIUS HEALTH INC.: PRODUCT PORTFOLIO
TABLE 040. RADIUS HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. MERCK & CO. INC.: SNAPSHOT
TABLE 041. MERCK & CO. INC.: BUSINESS PERFORMANCE
TABLE 042. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 043. MERCK & CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. NOVARTIS INTERNATIONAL AG: SNAPSHOT
TABLE 044. NOVARTIS INTERNATIONAL AG: BUSINESS PERFORMANCE
TABLE 045. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 046. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. PFIZER INC.: SNAPSHOT
TABLE 047. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 048. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 049. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. SUN PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 050. SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 051. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 052. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. TAKEDA PHARMACEUTICAL COMPANY LIMITED: SNAPSHOT
TABLE 053. TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS PERFORMANCE
TABLE 054. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 055. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. TEVA PHARMACEUTICAL INDUSTRIES LTD: SNAPSHOT
TABLE 056. TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS PERFORMANCE
TABLE 057. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 058. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. ALLERGAN PLC: SNAPSHOT
TABLE 059. ALLERGAN PLC: BUSINESS PERFORMANCE
TABLE 060. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 061. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. ELI LILY & COMPANY: SNAPSHOT
TABLE 062. ELI LILY & COMPANY: BUSINESS PERFORMANCE
TABLE 063. ELI LILY & COMPANY: PRODUCT PORTFOLIO
TABLE 064. ELI LILY & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 065. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 066. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 067. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. BISPHOSPHONATES MARKET OVERVIEW (2016-2028)
FIGURE 013. PARATHYROID HORMONE THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. RANK LIGAND INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 017. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 018. INJECTABLE MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 020. NORTH AMERICA OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. EUROPE OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. ASIA PACIFIC OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. MIDDLE EAST & AFRICA OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. SOUTH AMERICA OSTEOPOROSIS TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Osteoporosis Treatment Market research report?

The forecast period in the Osteoporosis Treatment Market research report is 2022-2028.

Who are the key players in Osteoporosis Treatment Market?

Amgen Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Radius Health Inc. (the US), Merck & Co. Inc. (US), Novartis International AG (Switzerland), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), Allergan Plc (Ireland), Eli Lily and Company (US), and other major players.

What are the segments of the Osteoporosis Treatment Market?

The Osteoporosis Treatment Market is segmented into Drug Class, Route of Administration, and region. By Drug Class, the market is categorized into Bisphosphonates, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, Others. By Route of Administration, the market is categorized into Oral, Injectable, Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Osteoporosis Treatment Market?

Osteoporosis is also called a silent disease as there are no symptoms until a bone is broken or there is a fracture in one or more vertebrae. The growing prevalence of osteoporosis in older individuals is stimulating the expansion of the osteoporosis treatment market over the forecast period.

How big is the Osteoporosis Treatment Market?

The Osteoporosis Treatment Market was valued at USD 12.61 Billion in 2021 and is projected to reach USD 17.39 Billion by 2028, growing at a CAGR of 4.7% from 2022 to 2028.